We are live on
!
Find out more
Qube Research & Technologies (QRT) Portfolio holdings
AUM
$89.9B
1-Year Est. Return
20.22%
This Fund
S&P 500
This Quarter
Est. Return
+6.9%
1 Year Est. Return
+20.22%
3 Year Est. Return
+42.42%
5 Year Est. Return
+23.97%
10 Year Est. Return
–
AUM
$98.4B
AUM Growth
+$12.2B
(+14%)
Cap. Flow
+$4.67B
Cap. Flow
% of AUM
4.75%
Top 10 Holdings %
Top 10 Hldgs %
7.81%
Holding
4,101
New
656
Increased
1,629
Reduced
1,101
Closed
596
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$486M |
| 2 |
Apple
AAPL
|
+$485M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$479M |
| 4 |
Uber
UBER
|
+$376M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$363M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$1.02B |
| 2 |
Meta Platforms (Facebook)
META
|
+$675M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$545M |
| 4 |
Microsoft
MSFT
|
+$482M |
| 5 |
Applied Materials
AMAT
|
+$404M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.24% |
| 2 | Financials | 10.53% |
| 3 | Industrials | 10.31% |
| 4 | Healthcare | 10.01% |
| 5 | Consumer Discretionary | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3026
iShares ESG Advanced MSCI USA ETF
USXF
$1.42B
| $105K | ﹤0.01% |
+1,945
| New | +$95K |
|
3027
Schwab Fundamental International Small Company Index ETF
FNDC
$3.04B
| $105K | ﹤0.01% |
2,488
-5,492
| -69% | -$213K |
|
3028
Ostin Technology Group
OST
| $104K | ﹤0.01% |
+26,404
| New | +$2.67M |
|
3029
Lantronix
LTRX
$240M
| $104K | ﹤0.01% |
36,358
-22,248
| -38% | -$50.5K |
|
3030
Blue Ridge Bankshares
BRBS
$309M
| $104K | ﹤0.01% |
29,024
-266,895
| -90% | -$899K |
|
3031
ProShares Bitcoin Strategy ETF
BITO
$1.42B
| $103K | ﹤0.01% |
4,786
+3,286
| +219% | +$67.8K |
|
3032
Treace Medical Concepts
TMCI
$271M
| $102K | ﹤0.01% |
+17,408
| New | +$113K |
|
3033
State Street SPDR Portfolio Europe ETF
SPEU
$719M
| $102K | ﹤0.01% |
2,103
-279
| -12% | -$12.9K |
|
3034
PUT
BILL Holdings
BILL
$4.51B
| $102K | ﹤0.01% |
+2,200
| New | +$97.3K |
|
3035
Patterson-UTI
PTEN
$3.75B
| $101K | ﹤0.01% |
+17,023
| New | +$102K |
|
3036
Zevra Therapeutics
ZVRA
$585M
| $99.4K | ﹤0.01% |
+11,288
| New | +$91.6K |
|
|
HLVX
3037
DELISTED
HilleVax
HLVX
| $99.4K | ﹤0.01% |
+49,963
| New | +$91.4K |
|
3038
Vanguard Russell 1000 Growth ETF
VONG
$42.7B
| $99.4K | ﹤0.01% |
910
-8,777
| -91% | -$864K |
|
3039
TScan Therapeutics
TCRX
$54.5M
| $99K | ﹤0.01% |
+68,286
| New | +$98.7K |
|
3040
1stdibs.com
DIBS
$154M
| $98.6K | ﹤0.01% |
+35,845
| New | +$92.9K |
|
3041
Vanguard Extended Market ETF
VXF
$30.6B
| $97.9K | ﹤0.01% |
+508
| New | +$90.2K |
|
3042
Vanguard FTSE Pacific ETF
VPL
$8.11B
| $97.4K | ﹤0.01% |
1,185
+1,033
| +680% | +$78.8K |
|
3043
Avantis US Equity ETF
AVUS
$14B
| $97.2K | ﹤0.01% |
964
+144
| +18% | +$13.5K |
|
3044
JPMorgan BetaBuilders US Equity ETF
BBUS
$8.8B
| $96.6K | ﹤0.01% |
863
-968
| -53% | -$100K |
|
3045
CALL
DuPont de Nemours
DD
$18.7B
| $96K | ﹤0.01% |
1,115
+557
| +100% | +$46.3K |
|
3046
XBiotech
XBIT
$68.6M
| $95.7K | ﹤0.01% |
+32,218
| New | +$93.7K |
|
3047
374Water
SCWO
$38.1M
| $93.2K | ﹤0.01% |
+28,726
| New | +$96.6K |
|
3048
American Well
AMWL
$189M
| $93.1K | ﹤0.01% |
10,470
-8,459
| -45% | -$60.5K |
|
3049
Sera Prognostics
SERA
$86.1M
| $92.5K | ﹤0.01% |
+33,382
| New | +$82.6K |
|
3050
Fidelity MSCI Materials Index ETF
FMAT
$590M
| $91K | ﹤0.01% |
+1,824
| New | +$87.5K |
|
Similar funds
Qube Research & Technologies (QRT)'s Q2 2025 Portfolio in Review
As of Q2 2025, Qube Research & Technologies (QRT) held 4,101 positions worth $98.4B, up 14% from $86.2B the previous quarter. Its ten largest holdings account for 7.8% of the portfolio.
Qube Research & Technologies (QRT) deployed $4.67B of net new capital in Q2 2025, opening 656 new positions and adding to 1,629 existing holdings. Its largest new stake was Bristol-Myers Squibb: 9,752,683 shares worth $451M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $675M trimmed.
- Qube Research & Technologies (QRT)'s largest Q2 2025 buy was Bristol-Myers Squibb: 9,752,683 shares worth $451M.
- Qube Research & Technologies (QRT) added most to Thermo Fisher Scientific in Q2 2025, an estimated $486M increase.
- Qube Research & Technologies (QRT)'s biggest Q2 2025 reduction was Meta Platforms (Facebook), cutting an estimated $675M.
- Qube Research & Technologies (QRT) fully exited Broadcom in Q2 2025, selling an estimated $1.02B.
- Qube Research & Technologies (QRT)'s ten largest holdings make up 7.8% of its $98.4B portfolio in Q2 2025.
- Qube Research & Technologies (QRT) opened 656 new positions and closed 596 in Q2 2025.
- Qube Research & Technologies (QRT)'s portfolio value rose 14% quarter-over-quarter to $98.4B.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2025, filed 14 Aug 2025.